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Pseudomonas aeruginosa (PA) status influences management decisions in cystic fibrosis (CF) but diagnostic 
approaches vary. We evaluated the ability of the CFHH criteria, which consist of two major and four minor 
statements, in diagnosing chronic PA infection among adults with CF.   
 
Methods  
In this retrospective cross-sectional analysis, we compared the CFHH criteria against the Leeds criteria. Data 
were collected between 1
st
 January and 31
st
 December 2016 from all adults with CF receiving care at 
Sheffield, excluding those with lung transplantation (n=7) or on ivacaftor (n=13). The CFHH criteria PA status 
were cross-tabulated against the Leeds criteria, and clinical outcomes between chronic PA vs non chronic 
PA for both criteria were compared. 
 
Results  
This analysis included 186 adults with CF (90 females, median age 27 years, median baseline FEV1 78.5%). 
The CFHH criteria diagnosed more cases of chronic PA (116/186, 62.4% vs 79/186, 42.5%), and 37/107 
cases of non-chronic PA according to the Leeds criteria were deemed chronic PA by the CFHH criteria. The 
magnitude of difference in %FEV1 decline between chronic PA vs non chronic PA was slightly greater for the 
CFHH criteria (–0.6%, 95% CI –1.8 to 0.6%) compared to the Leeds criteria (–0.2%, 95% CI –1.3 to 1.0%). 
 
Conclusions  
The CFHH criteria detected more cases chronic PA yet still retained similar levels of discrimination for health 
outcomes in comparison to the Leeds criteria. These findings provide preliminary evidence for the validity of 










Cystic fibrosis (CF) is a genetic life-limiting long-term condition characterised by increased susceptibility to 
recurrent lung infections by resistant pathogens, which leads to progressive lung damage and respiratory 
failure [1]. An important CF lung pathogen is Pseudomonas aeruginosa (PA). It is the most prevalent chronic 
pathogen among adults with CF [2] and once acquired, it is associated with worse prognosis in terms of 
accelerated %FEV1 decline and increased pulmonary exacerbation rates [3]. PA status influences various 
clinical decisions including clinical segregation, the choice of preventative inhaled therapies and the choice 
of intravenous antibiotics to treat exacerbations [4]. Accurate determination of PA status is therefore 
important in the management of people with CF. For example, long-term inhaled antibiotics which reduce the 
risk of exacerbation and improve %FEV1 among people with chronic PA infection [5] may not be initiated if 
that diagnosis was missed.  
 
The most commonly used definition for PA status in CF epidemiological research is the Leeds criteria. 
Chronic PA infection according to the Leeds criteria requires >50% of months in the preceding 12 months 
with respiratory samples that were positive for PA [4]. Thus the Leeds criteria set a high threshold for the 
diagnosis of chronic PA infection, creating criteria that are very specific. For example, if an adult provided 
nine sputum samples over seven months in the previous year and PA was cultured in three of those months, 
that person would not be diagnosed as chronic PA according to the Leeds criteria even if most of the 
samples (e.g. five of nine) were PA positive. However, studies have demonstrated that the Leeds criteria are 
insensitive with a tendency to mis-diagnose chronic PA as intermittent infection [6, 7]. The major clinical 
guidelines in CF [5, 8, 9] do not define PA status according to the Leeds criteria; and definitions of PA status 
in clinical trials targeting adults with chronic PA infection have used various definitions [10]. Clinicians are 
also unlikely to use the Leeds criteria in their day-to-day work. Our previous study showed that clinicians do 
not always agree with the Leeds criteria in determining PA status; instead they assimilate other relevant 
information e.g. the type of respiratory samples and strain typing results [11].  
 
In response, we have used a consensus method to develop a pragmatic set of criteria for defining chronic 
PA infection (i.e. the CFHH criteria) which encompasses several components including results of respiratory 
samples, anti-Pseudomonas IgG antibody levels, VNTR typing/genotyping and clinical context [12]. The 
diagnostic properties of the CFHH criteria have not been tested. This is the first evaluation of the CFHH 





This is a retrospective cross-sectional analysis of prospectively collected data from adults receiving care at 
the Sheffield Adult CF Centre throughout 2016. Regulatory approval for this study was obtained from NHS 
Health Research Authority (IRAS number 210313). 
 
All adults with CF were included, except those with lung transplantation (n=7) or on ivacaftor (n=13). Lung 
transplantation alters lung microbiome, which makes the interpretation of PA status difficult [13]. Ivacaftor 
reduces the likelihood of culturing PA, which may affect the diagnostic properties of the Leeds criteria [14]. 
Clinical data from 1
st
 January to 31
st
 December 2016 (demographics including social deprivation [15], 
microbiological results, prescriptions and health outcomes) were extracted from paper notes and electronic 
patient record, with all data from paper notes reviewed by two investigators to ensure accuracy. Objective 
adherence data were downloaded from I-neb
®
, a data-logging nebuliser system. The Leeds criteria [4] were 
operationalised using an algorithm according to results (PA positive / negative) of cough swab and sputum 
samples. The multi-component CFHH criteria [12] were operationalised by an investigator with clinical 
experience in CF (HZH) who reviewed all relevant primary data and the resultant PA status was 
independently checked by an experienced CF clinician (RC) to ensure accuracy. Further details of the CFHH 
criteria are provided in Appendix A. 
 
Since the CFHH criteria only categorises PA status as ‘chronic’ and ‘not chronic’ [12], the Leeds criteria 
categories were also combined into these two groups (i.e. ‘chronic PA infection’ = ‘chronic’; ‘intermittent’, 
‘free from infection’ and ‘never’ = ‘not chronic’) for the purpose of analysis. Four analyses were carried out to 
evaluate the clinical properties of the CFHH criteria. First, the CFHH criteria PA status was cross-tabulated 
against the Leeds criteria, with agreement in PA status for both criteria calculated using kappa statistics [16]. 
Second, clinical outcomes (best %FEV1 i.e. highest %FEV1 reading obtained in 2016 calculated using the 
GLI equation [17], %FEV1 decline from 2015 to 2016, %FEV1 variability [18], BMI, number of pulmonary 
exacerbations and days on intravenous antibiotics) were compared between ‘chronic PA infection’ and ‘non 
chronic PA’ for both criteria using non-parametric methods [19]; as was the proportion of adults on long-term 
inhaled antibiotics [20]. Third, the likelihood of ‘chronic PA infection’ according to both criteria were 
compared among the subgroup of adults in which respiratory cultures are less likely to be sensitive (i.e. 
adults with high adherence to inhaled therapies [21, 22], adults who predominantly provide cough swabs and 
adults ≤25 years [11]). Finally, the clinical variables associated with ‘chronic PA infection’ according to the 
CFHH criteria were explored. 
 
All analyses were performed using SPSS v25 (IBM Corp) and R v3.5.0 (www.r-project.org). Appropriate 
descriptive statistics were generated, including effect sizes and confidence intervals. P-values <0.05 were 





This analysis included 186 adults, with median age of 27 years (IQR 21 to 34 years) and 90 (48.4%) were 
females. More adults were deemed ‘chronic PA’ according to the CFHH criteria compared to the Leeds 
criteria (116, 62.4% vs 79, 42.5%), see Table 1. Where there was disagreement in PA status between the 
CFHH criteria and the Leeds criteria (37/186, 19.9%), the CFHH criteria diagnosed ‘chronic PA’ whereas the 
Leeds criteria diagnosed ‘not chronic PA’, see Table 2. There was only modest agreement in PA status for 
both sets of criteria; Cohen’s kappa coefficient 0.62, 95% CI 0.51 to 0.72. The demographic and clinical 
characteristics of the concordant and discordant groups were described in Appendix B. 
 
PA status according to both criteria discriminated the lung health of this cohort, see Table 3. The magnitude 
of difference was somewhat greater in baseline %FEV1, %FEV1 variability, number of exacerbations and 
intravenous days for the Leeds criteria. However, the converse was true for %FEV1 decline (–0.6%, 95% CI   
–1.8 to 0.6% vs –0.2%, 95% CI –1.3 to 1.0%) and BMI (1.8, 95% CI 0.5 to 3.0 vs 1.6, 95% CI 0.4 to 2.8) 
which somewhat favoured the CFHH criteria. The prescription of long-term inhaled antibiotics also matched 
the CFHH criteria better, with larger differences between those deemed ‘not chronic PA’ vs ‘chronic PA’ 
compared to the Leeds criteria (–59.7%, 95% CI –70.2 to –46.6% vs –38.5% 95% CI –48.6 to –26.7%). The 
likelihood of being deemed ‘chronic PA’ according to the CFHH criteria was less affected by high nebuliser 
adherence (difference in percentage of 7.1, 95% CI –9.7 to 28.7 vs 8.2, 95% CI –7.7 to 23.4), predominantly 
cough swabs provided (difference in percentage of 28.4, 95% CI 14.0 to 41.6 vs 48.2, 95% CI 35.6 to 58.2) 
or younger age (difference in percentage of 20.9, 95% CI 6.2 to 34.6 vs 37.0, 95% CI 23.0 to 48.8), see 
Table 4. 
 
Of the 116 adults deemed ‘chronic PA’ according to the CFHH criteria, 77 (66.4%) had positive PA cultures 
in ≥3 separate calendar months. There were 31 adults (26.7%) who only fulfilled one other minor criterion 
(see Appendix A for details of the CFHH criteria) and were deemed ‘chronic PA’ due to being on long-term 
inhaled antibiotics, see Table 5. Even if every adult in the centre were on long-term inhaled antibiotics, there 
would only be additional eight adults deemed ‘chronic PA’. Pseudomonas antibody testing and molecular 
(variable number tandem repeat, VNTR) typing were only performed in around 40% of the adults who 
required these tests. The lack of VNTR typing did not affect the diagnosis of chronic PA in this cohort but this 





In this analysis, we found that the CFHH criteria diagnosed many more cases of chronic PA infection among 
adults with CF in comparison to the Leeds criteria – all chronic PA cases according to the Leeds criteria were 
also chronic with the CFHH criteria but 37/107 (34.6%) of non-chronic PA cases according to the Leeds 
criteria were diagnosed as chronic PA according to the CFHH criteria. Despite identifying many more cases 
of chronic PA, the CFHH criteria still retained similar discrimination power for health outcomes among adults 
with CF. In particular, the difference in FEV1 decline between non-chronic PA and chronic PA favoured the 
CFHH criteria, and FEV1 decline is an important predictor of CF survival [23]. Since there is no perfect 
reference judge in the diagnosis of chronic PA among adults with CF, the “fair umpire” test [24] could be 
applied to aid judgments about the value of the CFHH criteria. The principle of this test is to judge the 
consequence of a new reference test by studying the subgroup with disagreements between the old and new 
reference tests. Possible umpire tests include exploration of prognosis [24]. The exploratory analyses in 
Appendix B showed that adults with discordant PA status for both criteria have similar FEV1 decline 
compared to adults who were concordant chronic PA. Therefore, a consequence of accepting the CFHH 
criteria as the reference standard to define PA status among adults with CF is the identification of additional 
chronic PA cases with similar prognosis to those with “definite” chronic PA i.e. the additional cases are less 
likely to be merely false-positive results. It could be argued that the shift in diagnosis with the CFHH criteria 
is desirable because a net benefit may be achieved by identifying those who may otherwise deteriorate 
without long-term inhaled antibiotics.   
 
Whilst it is important to avoid missing a diagnosis of chronic PA so that efficacious treatments can be 
initiated, it is nonetheless important to consider the robustness of the diagnosis due to its potential 
psychological impact [25]. Additional cases diagnosed as chronic PA by the CFHH criteria were mainly 
picked up among the subgroup of adults in which the Leeds criteria are known to be less sensitive (younger 
adults and adults predominantly providing cough swabs), which again suggest these are less likely to be 
merely false-positive results. Most of the chronic PA diagnosis (79/116, 68.1%) were made according to the 
major criteria though a sizable minority (31/116, 26.7%) depended on the use of long-term inhaled antibiotics 
for the diagnosis to be clinched. There is a discretionary element to the prescription of inhaled antibiotics, 
with variation between centres or even between individual clinicians at the same centre [26]. It is also 
possible that inhaled antibiotics were prescribed to target lung pathogens other than PA. Nonetheless, the 
inhaled antibiotics minor criterion does not necessarily render the CFHH criteria vulnerable to false-positive 
results, since chronic PA can only be diagnosed if there is another evidence to support that diagnosis. 
Indeed, even if the proportion of adults in Sheffield prescribed long-term inhaled antibiotics were increased 
from 72% to 100%, only an additional eight cases of chronic PA would be diagnosed with the CFHH criteria. 
  
Perhaps a more important factor to consider is that the CFHH criteria is maximally sensitive if all necessary 
investigations are performed. All major CF guidelines recommend that respiratory samples should be 
collected during every clinical review and that clinical reviews should occur at least every three months [27, 
28]. In Sheffield, 156/186 (83.9%) of the cohort provided at least four respiratory cultures during 2016. 
However, the frequency and access to Pseudomonas antibody testing and VNTR typing / genotyping are not 
specified in current care guidelines. In Sheffield, the aim is to perform Pseudomonas antibody testing during 
annual reviews among adults without any positive PA culture in the previous year. This was only performed 
among 46/78 (59.0%) of the adults without positive PA culture throughout 2016. Likewise, VNTR typing 
could have helped clarify the diagnosis of chronic PA among adults with only one positive PA culture but it 
was only performed among 10/18 (55.6%) of those adults. As a result, the CFHH criteria may have 
potentially missed the diagnosis of chronic PA in eight adults. Despite this limitation, we have noted a greater 
discrepancy between the Leeds criteria and the CFHH criteria (kappa 0.62) in comparison to our previous 
study which compared the Leeds criteria against clinicians’ diagnosis (kappa 0.72 for a 2x2 comparison 
within the 2015 Sheffield cohort) [11]. This highlights the potential advantages of using a set of objective and 
standardised criteria to diagnose chronic PA instead of relying on subjective clinician judgement – different 
clinicians (even those working in the same centre) will have different thresholds in diagnosing chronic PA 
and there may well be under-detection if clinicians do not all ‘sing from the same hymn sheet’. 
 
We acknowledge that our evaluation of the CFHH criteria has several limitations. A single centre study may 
lack generalisability. The Sheffield cohort is relatively young and centres with older adults are likely to find 
less discrepancy between the Leeds criteria and the CFHH criteria, since the prevalence of chronic PA 
infection increases with age, and older adults also tend to have lower FEV1 and become productive of 
sputum. Nonetheless, all adults diagnosed with chronic PA according to the Leeds criteria also fulfilled the 
CFHH criteria for chronic PA. This suggests that the CFHH criteria match the Leeds criteria but add value by 
achieving greater sensitivity in younger, healthier adults with minimal sputum and higher FEV1 where early 
detection of chronic PA can potentially prevent FEV1 deterioration, yet the diagnosis can be easily missed. It 
is likely that the CFHH criteria would still detect more cases of chronic PA in other cohorts. It might be 
argued that without a true ‘gold standard’, the only rigorous methodology to evaluate a new test which is 
more sensitive than an old test is to conduct a randomised trial assessing treatment efficacy in cases 
detected by the new diagnostic test [29]. However, such test-treatment trials are susceptible to various 
sources of bias including under-powering and inadequate primary analyses [30]. A large randomised trial to 
compare the effectiveness of different definitions of chronic PA among people with CF is also unlikely to be 
feasible due to the number of patients and centres required, and the expense of creating a rigorous detect 
and treat regimen.  
 
In conclusion, we have demonstrated that the CFHH criteria detected more cases chronic PA yet still 
retained similar levels of discrimination for health outcomes in comparison to the Leeds criteria. These 
additional cases were mainly detected in the subgroups in which the Leeds criteria are known to be less 
sensitive. If all necessary investigations specified in the CFHH criteria were performed, the criteria could 
have detected even more cases of chronic PA. Our findings provide preliminary evidence that the CFHH 
criteria is a valid and useful method to diagnose chronic PA among adults with CF. Further evaluation is 
planned in larger datasets to better understand the diagnostic properties of the CFHH criteria, in particular 
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Table 1: Demographic and clinical characteristics of study subjects 
  
Sheffield dataset 1 (n = 186) 
  
 
Age in years, median (IQR) 
 
 
Female, n (%) 
 
 
Pancreatic insufficient, n (%) 
 
 
CF related diabetes, n (%) 
 
 
Social deprivation (IMD quintile 2) 
        1 (least deprived), n (%) 
        2, n (%) 
        3, n (%) 
        4, n (%) 
        5 (most deprived), n (%) 
 
 
Number of relevant microbiological samples 
        Cough swabs, median (IQR) 
        Sputum samples, median (IQR) 
        Total, median (IQR) 
 
 
P. aeruginosa status (Leeds criteria) 
        Chronic P. aeruginosa infection, n (%) 
        Intermittent P. aeruginosa infection, n (%) 
        No P. aeruginosa, n (%) 
 
 
P. aeruginosa status (CFHH criteria) 
        Chronic P. aeruginosa infection, n (%) 
        Not chronic, n (%) 
 
 
Baseline %FEV1 in 2016, median (IQR) 
 
 
%FEV1 decline from 2015 to 2016 
3, median (IQR) 
 
 
%FEV1 variability in 2016 
4, median (IQR) 
 
 
BMI in kg/m2, median (IQR) 
 
 
Number of pulmonary exacerbations, median (IQR) 
 
 
Annual IV antibiotic days, median (IQR) 
 
 
On long-term inhaled antibiotics, n (%) 
 
 





















2 (0 to 4) 
4 (1 to 8) 














78.5 (58.5 to 89.6) 
 
 
–0.3 (–2.9 to 1.8) 
 
 
4.2 (2.5 to 89.6) 
 
 
23.2 (20.4 to 26.0) 
 
 
2 (1 to 3) 
 
 






 Complete data were available for every clinical variable, except one study subject did not have any FEV1 readings in 
2016 due to inability to perform spirometry testing, 10 study subjects did not have data for FEV1 decline due to the 
absence of FEV1 reading in 2015 and eight study subjects did not have data for FEV1 variability due to insufficient 
numbers of FEV1 readings in 2016.  
 
2
 Social deprivation was calculated as Index of Multiple Deprivation (IMD) scores, which were derived from postcodes 
using methods previously described [15]. 
 
3
 %FEV1 decline was the absolute change in %FEV1 from 2015 to 2016 and a negative value implies decline in %FEV1 
(more negative values imply a worse outcome). 
 
4
 %FEV1 variability was calculated as the median deviation of %FEV1 using methods previously described [18] (larger 
values imply a worse outcome). 




 Chronic P. aeruginosa 
infection 
Not chronic P. 
aeruginosa infection 
 
The Leeds criteria 
 
Chronic P. aeruginosa infection 











 For a more detailed breakdown, 15/78 (19.2%) of study subjects with no P. aeruginosa according to the Leeds criteria 
were defined as chronic P. aeruginosa according to CFHH criteria and 22/29 (75.9%) of study subjects with intermittent 
P. aeruginosa according to the Leeds criteria were defined as chronic P. aeruginosa according to CFHH criteria. 
 
  













Not chronic  




(n = 116) 
Median of  
differences between  
groups 
1
, (95% CI) 
 
 
Not chronic  




(n = 79) 
Median of  
differences between  
groups 
1





, median (IQR) 
 
 
%FEV1 decline from 2015 to  
2016 
3
, median (IQR) 
 
 





BMI, median (IQR) 
 
 
Number of pulmonary 
exacerbations, median (IQR) 
 
 
IV days, median (IQR) 
 
 
















































































–14 (–26 to –13) 
 
 
–59.7 (–70.2 to –46.6) 6 
 
 











































































–16 (–28 to –14) 
 
 
–38.5 (–48.6 to –26.7) 6 
 
1
 The between-group differences and confidence intervals for all continuous variables were estimated using a non-parametric method [19]. This method assumes the two groups have the same distribution 
shifted by a fixed parameter. The shift parameter is not necessarily the difference in median, rather it is the median of all possible differences. 
 
2
 Baseline %FEV1 was the highest %FEV1 reading obtained in 2016. % predicted was calculated using the GLI equation [17]. Data were available for 185/186 (99%) of the study subjects. 
 
3
 %FEV1 decline was the absolute change in %FEV1 from 2015 to 2016 and a negative value implies decline in %FEV1 (more negative values imply a worse outcome). Data were available for 176/186 
(95%) of the study subjects. 
 
4




 Long-term inhaled antibiotic was defined as inhaled antibiotics with intended treatment duration of >3 months. This included eradication treatment for non-tuberculous mycobacteria which is typically two 
years in duration. 
 
6




















Not chronic  




(n = 116) 
Differences in 
percentages between  
groups 
1
, (95% CI) 
 
 
Not chronic  




(n = 79) 
Differences in 
percentages between  
groups 
1





Cluster 1 (lowest adherence), n (%)  
Cluster 2, n (%) 
Cluster 3, n (%) 
Cluster 4 (highest adherence), n (%) 
 
 
Types of respiratory samples 
3
: 
Sputum ≥ cough swabs, n (%)  






Age >25 years, n (%)  
Age ≤25 years, n (%) 
 
 

































–5.9 (–19.1 to 14.4) 
–18.2 (–35.6 to 4.7) 
17.1 (–1.7 to 38.5) 




–28.4 (–41.6 to –14.0) 




–20.9 (–34.6 to –6.2) 
20.9 (6.2 to 34.6) 
 

































–9.2 (–24.2 to 5.7) 
–13.0 (–30.7 to 4.9) 
14.0 (–2.1 to 29.1) 




–48.2 (–58.2 to –35.6) 




–37.0 (–48.8 to –23.0) 
37.0 (23.0 to 48.8) 
 
1
 The difference in percentages and confidence intervals were calculated using the Wilson procedure without continuity correction [20]. 
 
2
 Objective adherence data from I-neb
®
 were available for 102 study subjects. Normative adherence was calculated then clustered according to previously described methods [21, 22]. The CFHH criteria 
Chi-square for trend p value = 0.120. The Leeds criteria Chi-square for trend p value = 0.048. 
 
3
 The CFHH criteria Chi-square p value <0.001. The Leeds criteria Chi-square p value <0.001. 
 
4
 The CFHH criteria Chi-square p value = 0.005. The Leeds criteria Chi-square p value <0.001.  
Table 5: Further exploration of P. aeruginosa status according to the CFHH criteria 
 
 
How was chronic P. aeruginosa infection status (n = 116) defined? 
 
≥3 months with positive samples, n (%) 
 
1 month or 2 months with positive samples, but on long-term inhaled antibiotics, n (%) 
 
Pseudomonas antibody +/– VNTR data required, n (%) 
 
Prior year data required, n (%) 
 
 
What was the relative contribution of long-term inhaled antibiotics towards the 
diagnosis of chronic P. aeruginosa status (n = 116)?  
 
Adults who fulfilled either of the major criteria, n (%) 
 
Adults who fulfilled minor criteria 1 & 3, n (%) 
 
Adults who fulfilled minor criteria 1 & 4, n (%) 
 
Adults who relied on long-term inhaled antibiotics to be defined as chronic PA, n (%) 
 
* Additional number of adults who would have been defined as chronic PA if everyone 
in the centre were prescribed long-term inhaled antibiotics  
 
 
Were all necessary investigations carried out to maximise the sensitivity of the CFHH 
criteria? 
 
Pseudomonas antibody testing: 
 
        Adults without any positive culture for P. aeruginosa in 2016 
 
        Adults without positive culture for P. aeruginosa and no Pseudomonas antibody 
 
        Adults without positive culture for P. aeruginosa that were deemed ‘non chronic 
        PA’ according to the CFHH criteria 
 
        ‘Non chronic PA’ without positive culture for P. aeruginosa and did not have  
        Pseudomonas antibody testing  
 
        * Additional number of adults who would have been defined as chronic PA if those 
        26 adults without Pseudomonas antibody testing actually had positive antibody 
 
Pseudomonas molecular (variable number tandem repeat, VNTR) typing: 
 
        Adults with positive culture(s) for P. aeruginosa for only one month in 2016 
 
        Adults with only 1-month positive culture for P. aeruginosa and no VNTR typing 
 
        Adults with only 1-month positive culture for P. aeruginosa that were deemed ‘non 
        chronic PA’ according to the CFHH criteria 
 
        ‘Non chronic PA’ with only 1-month positive culture for P. aeruginosa and did not  


































































Appendix A: A summary of the CFHH criteria to define P. aeruginosa status among adults with CF 
 
The full details of the CFHH criteria are outlined in our previous paper [1]. The criteria encompass several 
components including the number of positive respiratory samples, Pseudomonas antibody levels, molecular 
(VNTR) typing or genotyping and clinical context (e.g. types of respiratory samples collected and potential 
reasons for suppressed Pseudomonas aeruginosa, PA growth due to treatment factors). There are six 
criteria statements, two major and four minor. An adult with CF is deemed ‘chronic PA’ if any of major criteria 
is fulfilled or if any two of the minor criteria are fulfilled, see Table 1. 
 
Table 1: The six consensus statements to define chronic P. aeruginosa infection among adults with CF 
 
‘Major criteria’ statements (any one finding alone establishes the diagnosis of chronic P. aeruginosa infection) 
 
1. ≥3 respiratory samples positive for P. aeruginosa in the preceding 1 year, excluding samples collected 
during a recognised Pseudomonas eradication course (multiple positive samples within the same 
calendar month can only be counted once). 
 
2. ≥2 respiratory samples at least 3 months apart positive for P. aeruginosa in the preceding 1 year, 
excluding samples collected during a recognised Pseudomonas eradication course, among people who 
predominantly provide cough swabs (i.e. provide more cough swabs than sputum samples) 
 
 
‘Minor criteria’ statements (any two findings are required to establish the diagnosis of chronic P. aeruginosa infection) 
 
1. In the preceding 1 year; ≥1 respiratory sample positive for P. aeruginosa (excluding respiratory samples 
collected during a recognised Pseudomonas eradication course) AND / OR a strongly positive (e.g. >5 
ELISA unit or >2 OD unit) serum Pseudomonas IgG antibody level, or a trend of rising Pseudomonas 
IgG antibody levels (excluding serology samples collected during a recognised Pseudomonas 
eradication course) 
 
2. Insufficient number of respiratory samples positive for P. aeruginosa to fulfil the major criteria in a 
person with CF who is using long-term inhaled anti-pseudomonal antibiotic(s) {inhaled antibiotics 
prescribed for longer than 3 months are considered ‘long-term therapy’} 
 
3. ≥2 respiratory samples at least 6 months apart positive for P. aeruginosa of the same type (VNTR 
typing / genotyping) AND / OR a transmissible P. aeruginosa strain (e.g. Liverpool epidemic strain, 
Manchester epidemic strain or Midlands1 strain) 
 
4. A person who fulfilled the criteria for chronic P. aeruginosa infection in the previous year but did not 
provide adequate number of negative respiratory samples in the current year {That is to say the person 
did NOT provide any of the following: (a) at least x1 negative BAL sample OR (b) at least x4 negative 
sputum cultures OR (c) at least x6 negative respiratory samples of any kind, for example this might 
comprise of x1 negative sputum sample and x5 negative cough swabs. Note that multiple negative 
samples within the same calendar month can only be counted once and negative samples in a calendar 
month with any positive sample cannot be counted.} 
 
 
Major criterion #1 defines chronic PA infection on the basis that frequent sample positivity for PA would 
indicate chronic infection. It is important that multiple respiratory samples taken within a short time interval 
(e.g. during an admission for exacerbation) do not bias towards misclassifying intermittent PA infection as 
chronic, hence multiple positive samples within the same calendar month can only be counted once. 
Likewise, a positive sample during an eradication course is ignored since it may simply represent intermittent 
PA infection that can be subsequently eradicated. The Leeds criteria diagnosed chronic PA if can only be 
fulfilled if >50% of the months with respiratory samples were positive for PA [2]. Major criterion #1 does not 
include the proportion component of the Leeds criteria because the chronicity of someone with multiple 
positive samples (e.g. samples provided monthly and 5/12 were positive) would not be disputed just because 
other samples were negative.  
 
There will be occasions whereby major criterion #1 is not fulfilled in someone with chronic PA because 
cough swabs are less sensitive than sputum samples in culturing PA [3,4]. Therefore, major criterion #2 
defines chronic PA infection at a slightly lower threshold compared to major criterion #1 (2 months with 
positive samples instead of 3 months with positive samples) for someone who predominantly provide cough 
swabs. 
 
The minor criteria are less definitive than the major criteria in diagnosing chronic PA infection and should 
therefore be triangulated with at least another minor criterion in making the diagnosis. 
 
Minor criterion #1 looks for respiratory samples +/- serology evidence of current PA infection. Pseudomonas 
serology result only forms part of this minor criterion. Pseudomonas serology result is unnecessary to 
operationalise the CFHH criteria if a person with CF already has ≥1 positive respiratory samples in the 
previous 12 months, i.e. serology testing is only required to achieve a diagnosis among those without any 
positive samples. 
 
Minor criterion #2 considers the fact that a person may have insufficient positive samples to fulfil either of the 
major criteria if PA growth is suppressed by long-term inhaled anti-pseudomonal antibiotics. The PA growth 
suppression effect of inhaled anti-pseudomonal antibiotics depends on a multitude of factors and would vary 
from person to person. Due to the uncertainty regarding how much antibiotics is required to suppress PA 
growth, an adherence target was not specified for minor criterion #2. It is likely that someone not using 
inhaled anti-pseudomonal antibiotics for ≥12 months would definitely no longer benefit from any PA 
suppression effect. It is important to note that all the sample positivity criteria (e.g. major criterion #1, major 
criterion #2 and minor criterion #1) depend on respiratory samples over the previous 12 months. If someone 
ceased long-term inhaled anti-pseudomonal antibiotics 3 months previously (e.g. due to completion of a 2-
year M. abscessus eradication course with amikacin) and only provided a single cough swab sample since 
the cessation of inhaled antibiotics, that single negative sample certainly does not indicate the absence of 
PA infection. Therefore, it is specified that a person should cease long-term anti-pseudomonal inhaled 
antibiotics for ≥12 months in order NOT to fulfil this minor criterion; in that case we can be confident that their 
respiratory samples over the preceding 12 months are equally comparable with someone not on inhaled 
antibiotics.  
 
Minor criterion #3 considers evidence from molecular (VNTR) typing or genotyping of PA positive sample(s). 
VNTR and genotyping can only be performed if PA is cultured, so it follows that minor criterion #3 cannot be 
fulfilled in someone without any positive samples. Both identical VNTR type / genotype and transmissible 
strain are listed within the same minor criterion statement so that it is possible to de-diagnose chronic PA 
infection. If identical VNTR type / genotype and transmissible strain are listed as separate minor criteria, it 
would be possible to classify someone as chronically infected with just VNTR testing performed let say 2-3 
years ago (note there is no time limit as to when the VNTR testing was performed in the statement). This is 
undesirable because it would mean classifying someone as chronically infected even if strong evidence of 
PA eradication emerged later, e.g. negative BAL samples a year after cessation of long-term inhaled 
antibiotics. 
 
Minor criterion #4 considers the fact that people with high prior probability of being chronically PA infected 
may well remain chronically infected if there is insufficient evidence of them being free from PA infection. 
Multiple negative samples in the same calendar month could only be counted once to mirror the sampling 
interval condition of the major criterion #1. A positive sample within the same calendar month should trump 
the other negative samples, since standard respiratory cultures are not perfectly sensitive in detecting PA. 
 
If a particular investigation is required to clinch the diagnosis of chronic PA infection but the investigation 
(e.g. VNTR typing or Pseudomonas serology) was not performed, the CFHH criteria could still be 
operationalised. In this situation, the particular criterion (e.g. minor criterion #3) would be considered to be 
absent. For example, in someone who is on long-term inhaled antibiotics and provided x5 negative cough 
swabs throughout 2016, the absence of Pseudomonas serology means that minor criterion #1 is not fulfilled 
and that person would not be deemed to have chronic PA infection according to the CFHH criteria. 
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Appendix B: Exploring the demographic and clinical characteristics of study subjects with 
concordant and discordant P. aeruginosa status 
 







not chronic  





















Age in years, median (IQR) 
 
 
Female, n (%) 
 
 
Pancreatic insufficient, n (%) 
 
 
CF related diabetes, n (%) 
 
 
Social deprivation (IMD quintile 
2
) 
        1 (least deprived), n (%) 
        2, n (%) 
        3, n (%) 
        4, n (%) 
        5 (most deprived), n (%) 
 
 
Number of relevant microbiological samples 
        Cough swabs, median (IQR)  
        Sputum samples, median (IQR) 









%FEV1 decline from 2015 to 2016 
3




%FEV1 variability in 2016 
4










Number of pulmonary exacerbations, median (IQR) 
 
 
Annual IV antibiotic days, median (IQR) 
 
 
On long-term inhaled antibiotics, n (%) 
 
 

















3 (1 to 4) 
2 (0 to 5) 
5 (4 to 8) 
 
87.2  




(–2.6 to 2.4) 
 
 
3.9 (1.5 to 6.2) 
 
24.3  
(21.2 to 27.3) 
 
 
1 (0 to 2) 
 
 






















5 (1 to 7) 
1 (0 to 8) 
7 (5 to 11) 
 
78.6  




(–3.1 to 0.5) 
 
 
3.9 (2.5 to 6.4) 
 
23.1  
(21.2 to 25.2) 
 
 
1 (1 to 4) 
 
 






















0 (0 to 2) 
6 (4 to 9) 
7 (5 to 10) 
 
64.9  




(–3.3 to 1.6) 
 
 
5.1 (3.3 to 8.9) 
 
21.9  
(19.8 to 25.1) 
 
 
3 (2 to 5) 
 
 






 Complete data were available for every clinical variable, except one study subject did not have any FEV1 readings in 
2016 due to inability to perform spirometry testing, 10 study subjects did not have data for FEV1 decline due to the 
absence of FEV1 reading in 2015 and eight study subjects did not have data for FEV1 variability due to insufficient 
numbers of FEV1 readings in 2016.  
 
2
 Social deprivation was calculated as Index of Multiple Deprivation (IMD) scores, which were derived from postcodes 
using methods previously described [1]. 
 
3
 %FEV1 decline was the absolute change in %FEV1 from 2015 to 2016 and a negative value implies decline in %FEV1 
(more negative values imply a worse outcome). 
 
4
 %FEV1 variability was calculated as the median deviation of %FEV1 using methods previously described [2] (larger 
values imply a worse outcome). 
Among the 186 study subjects, 37 adults (19.9%) have discordant PA status whereby the Leeds criteria 
diagnosed non chronic PA whilst the CFHH criteria diagnosed chronic PA. This ‘discordant cohort’ was the 
youngest among all three groups and also provided more cough swabs and fewer sputum samples. These 
results are consistent with the findings in Table 4 of the main manuscript, which showed that the Leeds 
criteria were particularly insensitive for diagnosing chronic PA among younger adults and those who 
predominantly provide cough swabs. 
 
The ‘discordant cohort’ also had the %FEV1 decline (median –0.6%, IQR –3.1 to 0.5%) similar to those who 
were concordant chronic PA (median –0.5%, IQR –3.3 to 1.6%) and greater than those who were 
concordant non chronic PA (median 0.0%, IQR –2.6 to 2.4%). Since FEV1 decline is an important predictor 
of CF survival [3], this finding indicates the potential poor prognosis of the ‘discordant cohort’. The 
‘discordant cohort’ may have relatively high baseline %FEV1 compared to those who were concordant 
chronic PA (median 78.6%, IQR 62.6 to 91.0% vs median 64.9%, IQR 43.2 to 81.7%), but it must be noted 
that the ‘discordant cohort’ were on average 8 years younger (95% CI 5 to 11 years) and FEV1 declines at a 
rate of around 1.5%/year among people with CF [4]. 
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